NCT07900555
Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 7 words
- Secondary endpoints: details revised at 1 of 2 entries
- Study description expanded, about 5 words
- Study title expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Clinical and Biochemical Disease Control
Timeframe: Up to 10 years after radiotherapy
Secondary (2)
Late Toxicity
Acute toxicity
Arms and interventions
Hypofractionated focal boost radiotherapyExperimental
Image-guided IMRT in 25 fractions: 2.9 Gy/fraction (72.5 Gy) to the MRI-defined tumour, 2.4 Gy/fraction (60 Gy) to the uninvolved prostate and seminal vesicles, and 2.0 Gy/fraction (50 Gy) to the elective pelvic lymph nodes, with a boost of 2.4 Gy/fraction (60 Gy) to involved lymph nodes in node-positive patients; androgen deprivation therapy planned for 18 months.
Radiation: Hypofractionated IMRT with focal simultaneous integrated boost and elective pelvic irradiation
Drugs: Androgen Deprivation Therapy (ADT)
Sites
1 site in 1 country
- Haukeland University HospitalBergen, Vestland, Norway